<DOC>
	<DOCNO>NCT00617240</DOCNO>
	<brief_summary>The purpose pilot study determine whether start metformin conjunction second-generation antipsychotic ( SGA ) provide information healthy eating activity prevent reduce amount weight gain metabolic change adolescent youth typically see second-generation antipsychotic medication .</brief_summary>
	<brief_title>Strategies Reduce Antipsychotic-Associated Weight Gain Youth</brief_title>
	<detailed_description>This 24 week , placebo-controlled , random assignment pilot study participant randomize 1:1 ratio receive either flexible-dose treatment metformin 6 month well newly initiate second generation antipsychotic medication receive placebo newly initiate antipsychotic medication . All subject also provide healthy lifestyle instruction . The study involve monthly visit duration study . Participants may treat inpatient outpatient throughout course study . Participants receive psychiatric evaluation , physical exam , lab work , ECG , medication treatment , psychiatric care . The goal evaluate safety efficacy mean prevent treat weight gain associate endocrine , metabolic , inflammatory change cause antipsychotic medication . Behavioral treatment reduce weight gain metabolic problem weight gain occur little impact . Such intervention must intensive sustained month , year effective . Although basic lifestyle instruction ( diet physical activity ) standard care child adolescent risk become overweight , pharmacologic intervention may best option substantially augment behavioral approach weight management .</detailed_description>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Subjects age 10 17 , male female , race ethnicity Any SPMI pediatric diagnosis meet DSMIV criterion frequently treat SGA typically limit psychotic , mood , pervasive developmental , oppositional defiant , conduct disorder SGAna√Øve le 2 week exposure SGA , except ziprasidone Legal guardian able willing give write informed consent If competent , subject able willing assent participation Previous trial metformin Recommendation treatment clozapine ziprasidone Current use insulin oral hypoglycemic agent Current use medication know mitigate weight gain amantidine , histamine ( H2 ) antagonists ( cimetidine , ranitidine , nizatidine ) , topiramate , orlistat , sibutramine , stimulant ( dextroamphetamine , methylphenidate ) Any current past diagnosis eat disorder Diabetes mellitus Current active thyroid ( TSH &gt; 18 microIU/ml ; T4 total &gt; 18 mcg/dl ) , hepatic ( 2 LFTs &gt; 4x upper limit normal ) , renal ( serum Creatinine &gt; 1.4 mg/dL female serum Creatinine &gt; 1.5 mg/dL male ) , cardiac , gastrointestinal , adrenal disease Current substance abuse/dependence within past 2 week ; positive urine tox screen baseline absence meeting criterion abuse/dependence preclude enrollment . Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>antipsychotic</keyword>
	<keyword>metformin</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
</DOC>